Altimmune (ALT) Enterprise Value (2016 - 2025)
Altimmune (ALT) has disclosed Enterprise Value for 16 consecutive years, with -$61.3 million as the latest value for Q3 2025.
- On a quarterly basis, Enterprise Value rose 56.02% to -$61.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$61.3 million, a 56.02% increase, with the full-year FY2024 number at -$131.9 million, up 2.42% from a year prior.
- Enterprise Value was -$61.3 million for Q3 2025 at Altimmune, up from -$183.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$57.2 million in Q2 2024 to a low of -$201.9 million in Q3 2022.
- A 5-year average of -$149.3 million and a median of -$165.8 million in 2023 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: tumbled 355.19% in 2021, then skyrocketed 56.93% in 2023.
- Altimmune's Enterprise Value stood at -$190.4 million in 2021, then grew by 2.87% to -$184.9 million in 2022, then rose by 26.89% to -$135.2 million in 2023, then increased by 2.42% to -$131.9 million in 2024, then skyrocketed by 53.52% to -$61.3 million in 2025.
- Per Business Quant, the three most recent readings for ALT's Enterprise Value are -$61.3 million (Q3 2025), -$183.2 million (Q2 2025), and -$149.9 million (Q1 2025).